PMID- 35597430
OWN - NLM
STAT- MEDLINE
DCOM- 20231127
LR  - 20240314
IS  - 1873-2615 (Electronic)
IS  - 1050-1738 (Linking)
VI  - 33
IP  - 8
DP  - 2023 Nov
TI  - SGLT2 inhibitors in hypertension: Role beyond diabetes and heart failure.
PG  - 479-486
LID - S1050-1738(22)00072-X [pii]
LID - 10.1016/j.tcm.2022.05.005 [doi]
AB  - Type 2 Diabetes Mellitus (T2DM) is a pandemic that affects millions of patients 
      worldwide. Diabetes affects multiple organ systems leading to comorbidities 
      including hypertension. Sodium-glucose cotransporter 2 inhibitors (SGLT2i) 
      recently have been approved for the treatment of T2DM and heart failure with 
      reduced and preserved ejection fraction. Retrospective analyses of clinical 
      trials have noted SGLT2 inhibitors to have a promising effect on blood pressure. 
      Moreover, the observed blood pressure reduction is not just an acute effect of 
      treatment initiation but has been shown to have a long-term impact on both 
      systolic and diastolic blood pressure. The mechanism of action leading to the 
      blood pressure reduction is still unclear; however, proposed mechanisms are 
      related to the natriuretic effect, modification of the 
      renin-angiotensin-aldosterone system, and/or the reduction in the sympathetic 
      nervous system, SGLT2i should be considered as second-line medication in those 
      patients with diabetes or heart disease and concomitant hypertension. This 
      article reviews the pharmacology, side effect profile, and clinical trials 
      surrounding the use of SGLT2i for the treatment of hypertension.
CI  - Copyright (c) 2022. Published by Elsevier Inc.
FAU - Gupta, Rahul
AU  - Gupta R
AD  - Lehigh Valley Heart Institute, Lehigh Valley Health Network, Allentown, PA, USA. 
      Electronic address: rgupta8687@gmail.com.
FAU - Maitz, Theresa
AU  - Maitz T
AD  - Department of Medicine, Lehigh Valley Health Network, Allentown, PA, USA.
FAU - Egeler, David
AU  - Egeler D
AD  - Department of Medicine, Lehigh Valley Health Network, Allentown, PA, USA.
FAU - Mehta, Anila
AU  - Mehta A
AD  - Department of Medicine, Carle Foundation Hospital, Urbana, IL, USA.
FAU - Nyaeme, Mark
AU  - Nyaeme M
AD  - Department of Medicine, Carle Foundation Hospital, Urbana, IL, USA.
FAU - Hajra, Adrija
AU  - Hajra A
AD  - Department of Medicine, Jacobi Medical Center, Bronx, NY, USA.
FAU - Goel, Akshay
AU  - Goel A
AD  - Department of Cardiology, Westchester Medical Center and New York Medical 
      College, Valhalla, NY, USA.
FAU - Sreenivasan, Jayakumar
AU  - Sreenivasan J
AD  - Department of Cardiology, Westchester Medical Center and New York Medical 
      College, Valhalla, NY, USA.
FAU - Patel, Neel
AU  - Patel N
AD  - Department of Cardiology, Kansas University Medical Center, Kansas City, KS, USA.
FAU - Aronow, Wilbert S
AU  - Aronow WS
AD  - Department of Cardiology, Westchester Medical Center and New York Medical 
      College, Valhalla, NY, USA.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20220518
PL  - United States
TA  - Trends Cardiovasc Med
JT  - Trends in cardiovascular medicine
JID - 9108337
RN  - 0 (Sodium-Glucose Transporter 2 Inhibitors)
SB  - IM
MH  - Humans
MH  - *Sodium-Glucose Transporter 2 Inhibitors/adverse effects
MH  - *Diabetes Mellitus, Type 2/complications/diagnosis/drug therapy
MH  - Retrospective Studies
MH  - *Hypertension/diagnosis/drug therapy
MH  - *Heart Failure/diagnosis/drug therapy
OTO - NOTNLM
OT  - Clinical trials
OT  - Diabetes
OT  - Heart failure
OT  - Hypertension
OT  - SGLT2 inhibitors
EDAT- 2022/05/22 06:00
MHDA- 2023/11/27 12:44
CRDT- 2022/05/21 19:26
PHST- 2022/04/08 00:00 [received]
PHST- 2022/05/05 00:00 [revised]
PHST- 2022/05/14 00:00 [accepted]
PHST- 2023/11/27 12:44 [medline]
PHST- 2022/05/22 06:00 [pubmed]
PHST- 2022/05/21 19:26 [entrez]
AID - S1050-1738(22)00072-X [pii]
AID - 10.1016/j.tcm.2022.05.005 [doi]
PST - ppublish
SO  - Trends Cardiovasc Med. 2023 Nov;33(8):479-486. doi: 10.1016/j.tcm.2022.05.005. 
      Epub 2022 May 18.